Business
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics
About this update from Beam Therapeutics Inc.
[{"type":"image","alt":"Beam logo","displaySize":"","headline":null,"caption":"Beam logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":154,"url":"https://media.zenfs.com/en/globenewswire.com/9d2ec020ecd101e1c60cc6fb1efb6fdb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/aUAHg53n0Z2F5D8SUQVE7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9d2ec020ecd101e1c60cc6fb1efb6fdb","width":300,"height":154}},"lazy":false},{"type":"text","content":"New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026","length":166,"tagName":"p"},{"type":"text","content":"Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026","length":136,"tagName":"p"},{"type":"text","content":"Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026","length":267,"tagName":"p"},{"type":"text","content":"Expected Cash Runway Now into Mid-2029 Through Execution of Key Clinical, Regulatory and Commercial Milestones ","length":110,"tagName":"p"},{"type":"text","content":"Beam to Host Investor Webcast Today, February 24, 2026, at 8:00 a.m. ET","length":71,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported financial results for the fourth quarter and year ended December 31, 2025, and reiterated 2026 milestones. In addition, the company announced the expansion of its liver-targeted genetic disease franchise with a new program, BEAM-304, for the treatment of phenylketonuria (PKU), a disease with significant unmet need that affects approximately 20,000 individuals in the U.S.","length":564,"tagName":"p"},{"type":"text","content":"“In 2025, we established base editing as a best-in-class technology for genetic medicine, with positive proof-of-concept data and regulatory and clinical development paths to approval across multiple high-value...